Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy

@inproceedings{Odegard2015VirologicalAP,
  title={Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy},
  author={Jared M. Odegard and Brenna Kelley-Clarke and Semih U. Tareen and D. J. Campbell and Patrick A. Flynn and Christopher James Nicolai and Megan M Slough and Chintan D. Vin and Patrick J. McGowan and Lisa A. Nelson and Jan H. ter Meulen and Thomas W Dubensky and Scott H. Robbins},
  booktitle={Journal of immunotherapy},
  year={2015}
}
Dendritic cells (DCs) are essential antigen-presenting cells for the initiation of cytotoxic T-cell responses and therefore attractive targets for cancer immunotherapy. We have developed an integration-deficient lentiviral vector termed ID-VP02 that is designed to deliver antigen-encoding nucleic acids selectively to human DCs in vivo. ID-VP02 utilizes a genetically and glycobiologically engineered Sindbis virus glycoprotein to target human DCs through the C-type lectin DC-SIGN (CD209) and also… CONTINUE READING
Tweets
This paper has been referenced on Twitter 7 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Similar Papers

Loading similar papers…